Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.50 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350341 | 0.96 | ACE (0.54) | GRB2ACERENXIAPCMA1 | |
| SCHEMBL29482768 | 0.96 | ACE (0.54) | GRB2ACERENXIAPCMA1 | |
| SCHEMBL29641635 | 0.92 | GRB2 (0.60) | GRB2ACERENXIAPCMA1 | |
| SCHEMBL29974998 | 0.88 | ACE (0.49) | GRB2ACERENXIAPCMA1 | |
| SCHEMBL30455247 | 0.88 | CAPN1 (0.52) | GRB2XIAPCAPN1CTSBSLC6A2 | |
| SCHEMBL29396765 | 0.88 | CAPN1 (0.52) | GRB2XIAPCAPN1CTSBSLC6A2 | |
| SCHEMBL29427846 | 0.87 | ACE (0.62) | ACERENXIAPCMA1 | |
| SCHEMBL30397733 | 0.85 | XIAP (0.55) | GRB2ACERENXIAPSLC6A2 | |
| SCHEMBL29641611 | 0.85 | DPP4 (0.55) | GRB2ACERENXIAPCMA1 | |
| SCHEMBL31218906 | 0.85 | GRB2 (0.51) | GRB2ACERENXIAPCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409709-A1 | LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220089719-A1 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS (USA) LIMITED (US) | 2022-03-24 | — | — | US | disclosed |